Skip to main content

A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Start Date

May 1, 2016

End Date

April 30, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Start Date

May 1, 2016

End Date

April 30, 2022